SCHEMBL416600

SCHEMBL416600

Nc1cccc(-c2nc3cc(-c4ccc5[nH]c(-c6cccc(N)c6)nc5c4)ccc3[nH]2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.74
SMN1; SMN2 Q16637 10/20 0.74
NPC1 O15118 10/20 0.74
RAB9A P51151 10/20 0.74
KDM4E B2RXH2 10/20 0.74
HPGD P15428 9/20 0.74
TP53 P04637 5/20 0.74
HSD17B10 Q99714 4/20 0.74
PRMT1 Q99873 1/20 0.72
MAPT P10636 11/20 0.62
PKM P14618 5/20 0.62
GFER P55789 5/20 0.62
MEN1 O00255 8/20 0.62
KMT2A Q03164 8/20 0.62
POLB P06746 6/20 0.62
GAA P10253 5/20 0.62
USP2 O75604 4/20 0.62
BLM P54132 2/20 0.62
HTT P42858 3/20 0.58
TDP1 Q9NUW8 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17867450 0.94 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL29596534 0.92 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL29906364 0.92 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL9767334 0.92 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL57009 0.88 POLB (0.57) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL12351269 0.87 MEN1 (0.76) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL15443912 0.87 PRMT1 (0.82) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL15443952 0.86 PRMT1 (0.75) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL31063849 0.85 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL758845 0.85 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975416-B2 Antibacterial compounds SUMMIT CORPORATION PLC (GB) 2015-03-10 US claimed
EP-2373631-B1 ANTIBACTERIAL COMPOUNDS SUMMIT CORP PLC (GB) 2015-02-25 EP claimed
US-4390596-A POLYAMINE, BIS-MALEIMIDE, FREE RADICAL CATALYST, FILLER RHONE-POULENC INDUSTRIES (FR) 1983-06-28 US claimed
US-4238591-A BIS-MALEIMIDE, SILANEDIOL OR SILOXANE RHONE-POULENC INDUSTRIES (FR) 1980-12-09 US claimed
US-4225498-A Preparation of N-substituted oligo-imides RHONE-POULENC INDUSTRIES (FR) 1980-09-30 US claimed
US-9763925-B2 Antibacterial compounds SUMMIT THERAPEUTICS PLC (GB) 2017-09-19 US disclosed
EP-3095783-A1 ANTIBACTERIAL COMPOUNDS Summit Corporation Plc (GB) 2016-11-23 EP disclosed
US-20160184283-A1 ANTIBACTERIAL COMPOUNDS SUMMIT (OXFORD) LIMITED (GB) 2016-06-30 US disclosed
US-9314456-B2 Antibacterial compounds SUMMIT THERAPEUTICS PLC (GB) 2016-04-19 US disclosed
EP-2907813-A1 Antibacterial Compound Summit Corporation Plc (GB) 2015-08-19 EP disclosed
US-20150150861-A1 ANTIBACTERIAL COMPOUNDS SUMMIT (OXFORD) LIMITED (GB) 2015-06-04 US disclosed
US-8975416-B2 Antibacterial compounds SUMMIT CORPORATION PLC (GB) 2015-03-10 US disclosed
US-4013600-A STORAGE STABILITY RHONE-POULENC INDUSTRIES (FR) 1977-03-22 US disclosed
US-4012361-A Heat-stable polyimide resins from a bis-imide, a polyamine and an alazine RHONE-POULENC S.A. (FR) 1977-03-15 US disclosed
US-4010220-A AMINO COMPOUND, POLYURETHANE ELASTOMER RHONE-POULENC INDUSTRIES (FR) 1977-03-01 US disclosed
US-4005154-A Curing 1,2-epoxy with prepolymer based on polyamines and oligomers possessing imide groups RHONE-POULENC S.A. (FR) 1977-01-25 US disclosed
US-3998904-A POLYAMINES WITH IMIDE GROUPS RHONE-POULENC S.A. (FR) 1976-12-21 US disclosed
US-3970714-A Heat-stable polyimide resin modified by unsaturated polyester RHONE-POULENC S.A. (FR) 1976-07-20 US disclosed
US-3966678-A Maleic anhydride-polyaldimine prepolymers RHONE-POULENC S.A. (FR) 1976-06-29 US disclosed
US-3933745-A Imide copolymers possessing hydroxyl groups RHONE-POULENC S.A. (FR) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160184283-A1 ANTIBACTERIAL COMPOUNDS MRPL21, RPN2, ALPI ALDH1A1 1088/4885SMN1; SMN2 2597/4885NPC1 512/4885
US-20150150861-A1 ANTIBACTERIAL COMPOUNDS MRPL21, RPN2, ALPI ALDH1A1 1088/4885SMN1; SMN2 2597/4885NPC1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.